Dr. Daniel Amen shares his BRIGHTMINDS approach for preventing Alzheimer's, addressing 11 risk factors including blood flow, ...

The benefit-risk balance is tipping more in favor of Eli Lilly’s Kisunla in early Alzheimer’s disease as the FDA approves a ...

The exact numbers depended on the type of medication patients took, but the risk of developing Alzheimer’s was up to 70 ...

Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved a label ...

A new study by scientists has uncovered four groups of health problems that can eventually lead to Alzheimer's disease. It is ...

The FDA will allow a new dosing schedule for Eli Lilly’s Alzheimer’s drug Kisunla that could lessen a known side effect of ...

The U.S. Food and Drug Administration approved changing the prescribing information for Eli Lilly's Alzheimer's drug Kisunla to allow more gradual dosing to lower the risk of a potentially dangerous ...

Because Alzheimer’s is just one of several diseases that cause dementia, the key distinction lies in their scope.

UCLA Health researchers mapped four distinct pathways leading to Alzheimer’s disease using electronic health records.   The ...

Treating the neurodegenerative disease in its earlier stages is key to slowing cognitive decline. A new study offers hope for ...

People in early stages of the disease may show other signs of cognitive deterioration such as being unable to follow ...

Some breast cancer survivors may have a slightly reduced risk for Alzheimer’s disease, though the benefit appears to be ...